Disease · HP_0001907
Thromboembolism
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Thromboembolism. Diseases, record HP_0001907. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001907
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Thromboembolism
- Open Targets ID
- HP_0001907
- Other names
- Blood clot in blood vessel, Thromboembolic disease, Thromboembolic events
- Highest stage of its drugs
- Approval, for 3 of its 23 drugs, from DailyMed
Source Open Targets
Drugs23
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| HEPARIN SODIUM | CHEMBL1201657 | Oligosaccharide | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| LEPIRUDIN | CHEMBL1201666 | Protein | Approval | EMA Human Drugs, at withdrawal | 1 | 0 | 0 | Drugs and targets |
| WARFARIN SODIUM | CHEMBL1200879 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| WARFARIN | CHEMBL1464 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| RIVAROXABAN | CHEMBL198362 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| APIXABAN | CHEMBL231779 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| EDOXABAN | CHEMBL1269025 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BEMIPARIN | CHEMBL3707365 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ECULIZUMAB | CHEMBL1201828 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HEPARIN | CHEMBL4650299 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 23
See all 23 drugsTargets27
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| F10 | Coagulation factor X | 4 | Coagulation factor X inhibitor | Phase 3 | https://conductscience.org/library/genes/2159 | Drugs and targets |
| SERPINC1 | Antithrombin-III | 4 | Antithrombin-III activator | Approval | https://conductscience.org/library/genes/462 | Drugs and targets |
| VKORC1 | Vitamin K epoxide reductase complex subunit 1 | 3 | Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor | Approval | https://conductscience.org/library/genes/79001 | Drugs and targets |
| F2 | Prothrombin | 2 | Thrombin inhibitor | Approval | https://conductscience.org/library/genes/2147 | Drugs and targets |
| C5 | Complement C5 | 1 | Complement C5 inhibitor | Phase 3 | https://conductscience.org/library/genes/727 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 1 | HMG-CoA reductase inhibitor | Early phase 1 | https://conductscience.org/library/genes/3156 | Drugs and targets |
| OPRD1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4985 | Drugs and targets |
| OPRK1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4986 | Drugs and targets |
| OPRM1 | Opioid receptors; mu/kappa/delta | 1 | Opioid receptors; mu/kappa/delta antagonist | Phase 2 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| PLG | Plasminogen | 1 | Plasminogen inhibitor | Phase 3 | https://conductscience.org/library/genes/5340 | Drugs and targets |
1 to 10 of 27
See all 27 targetsTrials22
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00122317 | Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) | Phase 3 | 187 | 2017-06-05 | Paroxysmal Hemoglobinuria, Nocturnal | ECULIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04756128 | Impact of Colchicine and Low-dose Naltrexone on COVID-19 | Phase 2 | 142 | 2023-07-25 | Covid19 | COLCHICINE, NALTREXONE | Its record names the disease | ClinicalTrials.gov |
| NCT02684851 | The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery | Phase 3 | 87 | 2021-01-19 | Acetabular Fractures | TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT02392104 | Prospective Evaluation of an Extended Interval of INR Follow-up in a VA Anticoagulation Service | Not applicable | 51 | 2019-12-11 | Anticoagulation | WARFARIN | Its record names the disease | ClinicalTrials.gov |
| NCT02829957 | RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding | Phase 2/3 | 19 | 2023-05-10 | Venous Thromboembolism, Menstruation | APIXABAN, RIVAROXABAN | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT05687448 | DIrect Oral Anticoagulation and Bioprothesis Aortic Valve | Phase 3 | 1,500 | Aortic Valve Disease | APIXABAN | Its record names the disease | ClinicalTrials.gov | |
| NCT00162435 | Genetic Determinants of Warfarin Anticoagulation Effect | Not applicable | 500 | Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation | WARFARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT01019655 | Heparin for Pregnant Women With Thrombophilia | Phase 3 | 300 | Pregnancy and Thrombophilia | NADROPARIN CALCIUM | Its record names the disease | ClinicalTrials.gov | |
| NCT04593654 | Dosing of Thromboprophylaxis and Mortality in Critically Ill COVID-19 Patients | 257 | Covid19, Thromboembolism | DALTEPARIN SODIUM, TINZAPARIN | Its record names the disease | ClinicalTrials.gov | ||
| NCT03244319 | Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial) | Phase 3 | 220 | MV(Mitral Valve) Repair | EDOXABAN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 22
See all 22 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tranexamic vs Placebo: Number of Participants With a Thromboembolic Event | 1 of 45 | 0 of 42 | 87 | NCT02684851 | Trial comparisons |
| Tranexamic vs Placebo: Allogenic Blood Transfusion Rates | 21 of 45 | 13 of 42 | 87 | NCT02684851 | Trial comparisons |
| Tranexamic vs Placebo: deaths from any cause | 0 of 45 | 0 of 42 | 87 | NCT02684851 | Trial comparisons |
| Tranexamic vs Placebo: serious adverse events | 1 of 45 | 0 of 42 | 87 | NCT02684851 | Trial comparisons |
| Rivaroxaban vs Apixaban: Number of Participants Who Discontinued Planned Drug Administration | 4 of 8 | 2 of 11 | 19 | NCT02829957 | Trial comparisons |
| Rivaroxaban vs Apixaban: Number of Participants With Venous Thromboembolism (VTE) | 0 of 8 | 0 of 11 | 19 | NCT02829957 | Trial comparisons |
| Rivaroxaban vs Apixaban: Number of Patients That Held Drug for Menorrhagia | 0 of 8 | 0 of 11 | 19 | NCT02829957 | Trial comparisons |
| Rivaroxaban vs Apixaban: Number of Participants With Major Hemorrhage | 0 of 8 | 0 of 11 | 19 | NCT02829957 | Trial comparisons |
| Rivaroxaban vs Apixaban: Number of Participants Who Crossed Over to Another Anticoagulant | 3 of 8 | 1 of 11 | 19 | NCT02829957 | Trial comparisons |
| Rivaroxaban vs Apixaban: Number of Participants With Clinically Relevant Non-major Bleeding | 3 of 8 | 0 of 11 | 19 | NCT02829957 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials14
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 26892845 | RESULT | 1 | PubMed |
| 24837794 | RESULT | 1 | PubMed |
| 39575924 | DERIVED | 1 | PubMed |
| 35787831 | DERIVED | 1 | PubMed |
| 35426776 | DERIVED | 1 | PubMed |
| 34875111 | DERIVED | 1 | PubMed |
| 33779986 | DERIVED | 1 | PubMed |
| 33225952 | DERIVED | 1 | PubMed |
| 31752504 | DERIVED | 1 | PubMed |
| 30098707 | DERIVED | 1 | PubMed |
1 to 10 of 14
See all 14 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001907
GET https://conductscience.org/api/diseases/v1/HP_0001907/drugs?page=2